Blossomhill Therapeutics Inc BLSM

$14.63 -1.18 (-7.46%)

Valuation

Market cap
465,014,000
Revenue TTM
$0
Net income TTM
$-60,560,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
84,300
Avg volume
192,838
Day's range
$14.42 – $15.82
Shares out
31,785,000
Stochastic %K
34%
Beta
—
Analysts
Strong Sell
Price target
$35.40

Price

Company profile

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refra...

Show more

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
(858) 732-3880
Website
https://bhtherapeutics.com
Address
10255 Science Center Drive, Suite 200, San Diego, United States

Latest news

Stocktwits

Merlintrader Oct 23, 6:30 AM
$BLSM Latest company news, Oct 22, 2026: BlossomHill and Foundation Medicine will develop and validate a companion diagnostic for the EGFR C797S mutation, tied to the ongoing SOLARA study of BH-30643. In September SOLARA reported 18 responses (16 confirmed) among 40 patients with C797S-mutant lung cancer. New hub (BH-30643, SOLARA, IPO cash and runway): https://www.merlintrader.com/blossomhill-therapeutics-stock-hub/ Not investment advice.
0 replies
BioTuesdays Oct 22, 4:10 PM
$BLSM has announced a collaboration with Foundation Medicine, a wholly owned subsidiary of Roche (SIX: RO, ROP; OTCQX: RHHBY), to develop the first companion diagnostic assay (CDx) for BH-30643 in EGFR C797S-mutated non-small cell lung cancer (NSCLC) https://biotuesdays.com/2026/10/22/blossomhill-foundation-medicine-to-develop-first-cdx-for-bh-30643-in-egfr-c797s-mutated-nsclc/
0 replies
BossTrade Oct 7, 3:37 PM
$BLSM 168M ipo currently mc $550M Cash in hand 95M Lots more room to go down
1 replies
JohnBiotech Oct 7, 3:13 AM
$BLSM bought the dip
0 replies
Quantumup Sep 30, 1:04 PM
H.C. Wainwright y'day reitd $BLSM Buy-$35 after BlossomHill presented preclinical data for BH-501284 across multiple models at the AACR Conference on Pancreatic Cancer. $RVMD $IMRX LLY REGN ERAS TNGX BBOT ANL VSTM AZN AMGN AVBP CGEM MRK DSNKY BDTX ORIC JNJ Here's what H.C. Wainwright said in its note to investors: https://x.com/Quantumup1/status/2105282524222034161?s=20
0 replies
Quantumup Sep 21, 11:33 AM
Guggenheim⬆️ $BLSM's PT to $40 after⬆️PoS assumptions for BH-30643 in 1L EGFRm NSCLC)—BLSM reported 2Q26 results and provided a pipeline update consistent with recent disclosures; maintained Buy. $AVBP $CGEM MRK DSNKY BDTX ORIC AZN JNJ Here's what Guggenheim said in its note: https://x.com/Quantumup1/status/2101998018157244591?s=20
0 replies
Ranchocopper Sep 16, 6:49 PM
$BLSM Winner winner chicken dinner
0 replies
OpenOutcrier Sep 15, 12:15 PM
$BLSM (+4.4% pre) BlossomHill reports trial data for lung cancer drug candidate https://ooc.bz/l/114209
0 replies